Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of repeated local Surv.m-CRA-1 administration in advanced primary malignant bone tumor
jRCT2073210118Phase 2Suspended
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2022
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Surv.m-CRA-1 in bone cancer, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Overall response rate. Started Jan 2022; status: suspended.
02
Drugs
Surv.m-CRA-1
03
Conditions
bone cancer
Beyond the preview
Go deeper on jRCT2073210118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2073210118.